Welcome to our dedicated page for Walgreen Boots news (Ticker: WBA), a resource for investors and traders seeking the latest updates and insights on Walgreen Boots stock.
This page provides a focused view of news and announcements historically associated with Walgreens Boots Alliance, Inc. (formerly Nasdaq: WBA) and its related businesses, including Walgreens and Walgreens Specialty Pharmacy. Company communications highlight Walgreens as a U.S. retail pharmacy brand founded in 1901 that serves nearly 9 million customers and patients each day across approximately 8,500 stores in the U.S. and Puerto Rico, and Walgreens Boots Alliance as a pharmacy-led health and wellbeing enterprise formed through the combination of Walgreens and Alliance Boots.
News related to WBA and Walgreens has covered several key themes. One major area is corporate transactions and capital markets activity. In 2025, a series of announcements detailed the Agreement and Plan of Merger under which Blazing Star Merger Sub, Inc. merged with and into Walgreens Boots Alliance, Inc., resulting in the company becoming a wholly owned subsidiary of Blazing Star Parent, LLC, an affiliate of Sycamore Partners. Related releases described tender offers and consent solicitations for various series of Walgreens Boots Alliance and Walgreen Co. notes, pricing terms, extensions of expiration times and settlement dates, and the final results of these offers.
Another important news category involves the company’s transition from public to private ownership. A Form 8-K filed on August 28, 2025 describes the completion of the merger, the cash consideration and divested asset proceed rights received by shareholders, and the cessation of trading of WBA common stock and certain notes on Nasdaq. A subsequent Form 25 documents the removal of these securities from listing, and a Form 15 filed on September 8, 2025 terminates registration and suspends reporting obligations. Sycamore Partners separately announced the completion of its acquisition of Walgreens Boots Alliance, Inc. and its intention that Walgreens, The Boots Group, Shields Health Solutions, CareCentrix and VillageMD operate as standalone companies under private ownership.
Operational and healthcare-focused news also features prominently. Walgreens Specialty Pharmacy announced an expansion of its limited distribution drug network to 265 products, emphasizing its role in specialty medications for patients with rare, complex and chronic diseases and its independence from pharmacy benefit managers. Walgreens has also issued releases on vaccination services, including nationwide flu shot availability for individuals three years and older, walk-in and scheduled appointments, digital check-in features and incentives for myWalgreens members receiving vaccines.
Investors and observers using this news page can review historical coverage of WBA’s merger process, debt tender offers, governance and shareholder actions, as well as Walgreens’ specialty pharmacy initiatives and vaccination programs. For those tracking the evolution of the company, these articles collectively document WBA’s path from a publicly traded integrated healthcare and retail group to a privately held organization under Sycamore Partners, while also illustrating how Walgreens positions its pharmacies and specialty operations within the broader healthcare landscape.
Summary not available.
Walgreens is actively preparing for Hurricane Ian, prioritizing the safety of patients, customers, and team members in Florida. Under the State of Emergency, pharmacists can refill non-controlled medications for up to a 30-day supply without prescriber authorization. Walgreens will deploy mobile pharmacies and emergency power generators to areas potentially affected. The company emphasizes that customers should follow emergency directives and check the Walgreens website for updates. Senior VP Lisa Badgley affirmed the commitment to community well-being and operational readiness amidst the storm.
Walgreens Boots Alliance (WBA) announced its full acquisition of Shields Health Solutions for approximately $1.37 billion, completing a strategic move to strengthen its specialty pharmacy segment. This follows WBA's previous increase in stake to about 70% in September 2021. Shields has demonstrated robust growth with a 57% sales increase in the first nine months of fiscal 2022, enhancing WBA’s consumer-centric healthcare strategy. Additionally, WBA has restructured its U.S. leadership with changes to its pharmacy and retail divisions.
Walgreens announces participation in the inaugural cohort of 51 Labs, an accelerator dedicated to advancing women+’s health, particularly during menopause. The program, launched by MATTER, partners with Astellas Pharma US, Parkview Health, and the University of Chicago Medicine. It aims to foster healthcare solutions for the 1.3 million U.S. women entering menopause annually, addressing a historically underserved health segment. The cohort will focus on enhancing awareness and managing symptoms to improve overall health outcomes for women+ during this transition.
Walgreens Boots Alliance (WBA) will release its fourth quarter and fiscal 2022 earnings results on Oct. 13, 2022, at 7 a.m. Eastern time. The management will host a two-hour conference call starting at 8:30 a.m. Eastern time, which will be available via the WBA investor relations website. The replay will be accessible for a week post-call. With approximately 13,000 locations globally and over 315,000 employees, WBA continues to innovate in retail pharmacy and healthcare services, emphasizing well-being and community health.
Walgreens Boots Alliance (Nasdaq: WBA) has appointed Inderpal Bhandari to its board and Hsiao Wang as CIO, enhancing its leadership with expertise in IT for healthcare and retail. A new Finance and Technology Committee has been formed to focus on strategic growth in technology. Bhandari, previously IBM's global chief data officer, brings extensive IT experience, while Wang, an MIT graduate, previously led technology for The Michaels Company and Walmart. This leadership expansion aims to accelerate WBA's healthcare platform and improve customer experiences.
Walgreens has begun offering updated COVID-19 boosters from Pfizer and Moderna for individuals aged 12 and older, authorized by the FDA and CDC. These boosters target the Omicron variants BA.4 and BA.5, prevalent in the U.S. Appointments can be scheduled via the Walgreens app or online. Eligible individuals must have completed a primary vaccine series or received a booster at least 2 months prior. Additionally, Walgreens encourages simultaneous flu vaccinations to enhance community protection. Walgreens has administered nearly 70 million COVID-19 vaccines since the pandemic began.
Walgreens Boots Alliance (WBA) has completed a majority share acquisition of CareCentrix, investing $330 million for 55% ownership, valuing the company at $800 million. This strategic move enhances Walgreens Health's capabilities in home care, allowing better management of patients transitioning from hospitals. CareCentrix manages care for 19 million members across 7,400 providers, achieving a 20% reduction in total care costs. The partnership aims to improve healthcare delivery, reduce hospital readmissions, and enhance overall patient outcomes.
Summary not available.
Walgreens Boots Alliance (WBA) has sold 11 million shares of Option Care Health (OPCH) in a secondary offering, reducing its ownership from 20.5% to 14.4%. The proceeds will primarily be utilized for debt paydown and to support strategic priorities. CEO Rosalind Brewer emphasized the action aligns with the company's strategy and enhances balance sheet flexibility. Walgreens Boots Alliance continues to serve millions through over 13,000 locations worldwide, aiming to improve healthcare access.